News & Press

Dow AgroSciences and TeselaGen Advance Biodesign Technologies for Agriculture

Using the power of nature in conjunction with advanced technology and informatics to produce and develop solutions for farmers is essential to advance agriculture. Today, TeselaGen Biotechnology Inc., and Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW), announced they have entered into a collaboration to produce a state-of-the-art biological design automation platform that can speed discovery work.

Read More

TeselaGen receives NSF SBIR Award

TeselaGen has received a $750,000 grant from the National Science Foundation to expand its computer aided design platform for building and modifying DNA with synthetic biology techniques. The Small Business Innovation Research Phase II grant will be used to further commercialize the “j5” technology under exclusive license from the Lawrence Berkeley National Laboratory.

Read More

TechCrunch: TeselaGen Is Building A Platform For Rapid Prototyping in Synthetic Biology

Using the power of nature in conjunction with advanced technology and informatics to produce and develop solutions for farmers is essential to advance agriculture. Today, TeselaGen Biotechnology Inc., and Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW), announced they have entered into a collaboration to produce a state-of-the-art biological design automation platform that can speed discovery work.

Read More

TeselaGen wins Bio-IT World’s 2013 Best Practices Award

There are plenty of plaudits for organizations in the life sciences that change the industry’s conceptions of what is possible, but one purpose of the Bio-IT World Best Practices Awards is to highlight those who refine those achievements until the merely possible becomes truly practical. That is why Bio-IT World was pleased to award an honorable mention at the 2013 Best Practices Awards to TeselaGen Biotechnology, a startup that spun out from the Berkeley Lab’s Joint BioEnergy Institute (JBEI) in 2011, and Amgen for the development of TeselaGen: j5, an automated platform for designing DNA assembly protocols. This new, cloud-based platform allows even small institutions to quickly find the most cost-effective protocols for assembling scarless, multipart DNA.

Read More

Redbiotec and TeselaGen to Partner on Herpesvirus vaccine library

Redbiotec and TeselaGen have announced a joint venture to build a scalable, integrated, rapid design and rapid prototyping infrastructure for the creation of a library for Herpesvirus vaccine development. This library will enable new concepts for vaccines against Herpesviruses and will enable the optimization and improvement of new and existing vaccine candidates.

Read More